AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01400711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS perioperative care
Description: Patient's education before surgery, early mobilization and oral feeding after surgery, no opioids analgesics.
Study NCT01400711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: Nasogastric tube until bowel function, late oral eating, opioid analgesics.
Study NCT02499614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Eligible patients with ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID. The dose of crizotinib may be adjusted depending on the type and severity of toxicity encountered
Study NCT03747692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: study group
Description: local anesthesia by mepicaine hydrochloride by intracervical local injection using 10 mm syringe.
Study NCT03747692 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: each patient receives one tablet of NSAIDs (diclofenac sodium 50 mg) and 5ml of a placebo in form of normal saline are injected intracervical 5 minutes before the procedure using 10 mm syringe.
Study NCT00642291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if \<30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if >=7 to \<15kg; 10/2.5 mg/kg BID if >=15 to \<=40 kg)
Study NCT00642291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
Study NCT02970565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention
Description: The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact.
Study NCT02970565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Play Intervention
Description: Mothers and children in the Play and Nutrition group will play educational and nutrition-focused games.
Study NCT00601367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin flexible dose
Description: Initial dosage:~Patients were to take one 50 mg flibanserin tablet in the evening.~Subsequent dosage titrations:~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site.
Study NCT00893802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scaling and root planning
Description: Intervention will consist of supra and subgingival scaling and root planning performed by a single trained periodontist using Gracey curettes (Hu-Friedy, Chicago, USA) without local or general anesthesia during the second trimester of gestation, followed by professional prophylaxis and oral hygiene instruction. Treatment will be performed only once during study.
Study NCT00184925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheostomy
Description: trachesotomy with subglottic drainage
Study NCT01175122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H2N3 MO 2003/AA ca Vaccine
Description: 0.2 mL of H2N3 MO 2003/AA ca vaccine delivered by an Accuspray nasal spray device on Day 0 and Day 28
Study NCT01605994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-933043
Study NCT00184925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cannula with subglottic drainage
Study NCT00901069 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azacitidine with rituximab, vincristine, and cyclophosphamide
Description: Azacitidine cycle days 1-5 Cyclophosphamide cycle days 6-9 Vincristine cycle day 8 Rituximab cycle day 8 Rituximab is only for those patients with CD20+ lymphoma. Azacitidine 25 mg/m2\^ Azacitidine 50 mg/m2\^ Azacitidine 75 mg/m2\^ Azacitidine 100 mg/m2\^
Study NCT02808039 — intervention group
Intervention type: OTHER
Intervention: Platelet reactivity testing
Description: assessment of platelet aggregation using the VerifyNow purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) platelet function assay (Accumetrics, San Diego, California)
Study NCT03618134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03618134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Radical Neck Dissection
Description: Undergo modified radical neck dissection
Study NCT03618134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03618134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03618134 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT03618134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Robotic Surgery
Description: Undergo TORS
Study NCT03618134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT03547804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg qd/250mg
Study NCT03547804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
Study NCT03813706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lymph node dissection
Description: The right cervical central compartment VI is subdivided into right cervical central VI-1 subzone and VI-2 subzone. Right central VI-1 subzone lies anterior to the RLN bounded by the hyoid bone superiorly, the suprasternal notch inferiorly, the inner edge of the common carotid artery laterally, and the midline of the trachea medially. Right central VI-2 subzone lies posterior to the right RLN. The superior, inferior, lateral, and medial borders are the laryngeal entry points of RLN, the intersection of the RLN with the innominate artery (near the right apical pleura), the inner edge of the common carotid artery, and esophagus, respectively. The floor of right central VI-2 is the prevertebral fascia.
Study NCT03813706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node dissection
Description: The right cervical central compartment VI is subdivided into right cervical central VI-1 subzone and VI-2 subzone. Right central VI-1 subzone lies anterior to the RLN bounded by the hyoid bone superiorly, the suprasternal notch inferiorly, the inner edge of the common carotid artery laterally, and the midline of the trachea medially. Right central VI-2 subzone lies posterior to the right RLN. The superior, inferior, lateral, and medial borders are the laryngeal entry points of RLN, the intersection of the RLN with the innominate artery (near the right apical pleura), the inner edge of the common carotid artery, and esophagus, respectively. The floor of right central VI-2 is the prevertebral fascia.
Study NCT01511419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAIV H7N3
Description: 2 doses of vaccine
Study NCT01511419 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 doses of placebo
Study NCT02435277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Metformin
Description: 1100 mg L Leucine in combination with 125 mg of Metformin BID
Study NCT02435277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mid Metformin
Description: 1100 mg L Leucine in combination with 250mg Metformin BID
Study NCT02435277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Metformin
Description: 1100 mg of L Leucine in combination with 500 mg Metformin BID
Study NCT02435277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID
Study NCT00818324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-12759 Ophthalmic suspension
Description: Instillation,4times/day,for 52weeks
Study NCT00604058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis vaccine (IMOVAX)
Description: Fractional dose (1/5th) 0.1 mL, intradermally
Study NCT00604058 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Poliomyelitis vaccine (IMOVAX)
Description: A full dose, 0.5 mL, intramuscular
Study NCT03922360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-based Financial Incentives
Description: Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.~Best Practices + Financial Incentive- Women assigned to this condition will receive the best practices treatment described above plus the remote incentives intervention.~Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples \< 6 ppm will be considered negative and those > 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced and incentives will be contingent on submitting a negative saliva cotinine test.
Study NCT03922360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best Practices
Description: Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.
Study NCT03355599 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3d camera
Description: 3 D camera and associated software that introduces measurement and monitoring of wounds as a specific intervention
Study NCT03346369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate
Description: Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period
Study NCT02005848 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 Antitrypsin
Study NCT02005848 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01055808 — intervention group
Intervention type: DRUG
Intervention: Insulins
Description: Individual dose and frequency and duration as determined by the treating physician
Study NCT01980108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water
Description: water
Study NCT02644161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dense cranial electroacupuncture stimulation
Description: DCEAS is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20, +) and Yintang (EX-HN3, -), left Sishencong (EX-HN1, -) and Toulinqi (GB15, +), right Sishencong (EX-HN1, -) and Toulinqi (GB15, +), bilateral Shuaigu (GB8, L+, R-), bilateral Taiyang (EX-HN5, L+, R-), and bilateral Touwei (ST8, L+, R-).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz, 100 µs).
Study NCT01727713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Open Label: Once-Daily formulation of aripiprazole flex dose regimine
Study NCT02667860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis.
Description: Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
Study NCT02667860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal anastomosis
Description: A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.
Study NCT02667860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echelon Endopatch
Description: Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis.
Study NCT02667860 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proximate Linear Cutter
Description: Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis.
Study NCT02426411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMA401 200 mg
Study NCT02426411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMA401 600 mg
Study NCT02426411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03420378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Vitamin D replacement
Study NCT02433379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMBLEM S-ICD System
Description: The intervention comprises programming the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) with zone cutoffs at 200 bpm and 250 bmp
Study NCT04315376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-Diet Intervention
Description: The participants who performed exercise-diet intervention performed an Astrand-rhyming test before and after the exercise program intervention. Participants followed a progressive exercise-program during four months according to initial physical fitness. The main exercises consisted of improving aerobic, speed and resistance performance. During all single sessions, breathlessness and fatigue were measured using 0 to10 Borg scale. A personal trainer certified by American College of Sports Medicine (ACSM) supervised three sessions per week, the other two unsupervised training days the subjects were given the detailed training program to do in house/park. And also, this group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
Study NCT04315376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Intervention
Description: This group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
Study NCT02683525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant
Study NCT02816632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mRI
Description: Neural bases of feedbacks' influence on decision making processes
Study NCT03732391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG(milligram)/ML
Description: Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will be continued with the same schedule until unacceptable toxicity or disease progression
Study NCT02816632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of Galvanic Vestibular Stimulation on decision making processes
Description: Galvanic Vestibular Stimulation (GVS) stimulates the vestibular system through low intensity electric currents applied at the basis of the VIII cranial nerve, upon the mastoid processes. In the Right-Anodal condition the positive electric charge is applied through electrodes placed upon the right mastoid and it mainly activates structures within the left brain hemisphere. In the Left-Anodal condition the positive electric charge is applied through electrodes placed upon the left mastoid and it mainly activates structures within the right brain hemisphere. In the SHAM condition, low intensity electric currents are applied 5 cm below the mastoid processes. This condition does not activate the vestibular system and serves as a control condition to account for unspecific activating effects of all electric stimulations (e.g., arousal, discomfort). The three conditions will be applied in three different sessions (i.e. days) in randomized order.
Study NCT00681252 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: URLC10, VEGFR1 and VEGFR2
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
Study NCT00870831 — intervention group
Intervention type: OTHER
Intervention: OGTT (Oral Glucose Tolerance Test)
Description: Subjects would consume 75grams of sugar (Dextrose, 10 oz) and blood samples taken at specified time points to measure glucose, insulin and C-peptide
Study NCT03531177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEAL-D
Description: HEAL-D is a 7 session programme of self-management education and behaviour change support for African and Caribbean patients with type 2 diabetes. The sessions will support participants with behaviour change to adopt evidence-based diet and physical activity targets for type 2 diabetes. The intervention has been systematically developed with defined theory and behavioural change techniques mapped to this theory.
Study NCT03531177 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants receive usual care from their healthcare team.
Study NCT02644161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Body acupuncture
Description: Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Qu-Chi (LI11), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation at 15 min. No electrical stimulation is delivered.
Study NCT03949335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL Model ZFR00V
Description: Bilateral implantation with Investigational IOL Model ZFR00V
Study NCT03949335 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL Model ZCB00
Description: Bilateral Implantation with control IOL Model ZCB00
Study NCT01605994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-933043
Study NCT02644161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidepressant
Description: Patients will continue their existing antidepressant therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
Study NCT02403219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Description: Injection of botulinum toxin type A
Study NCT02403219 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline solution injection
Description: Injection of saline solution
Study NCT02299336 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept
Description: pro re nata (PRN)
Study NCT02299336 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Focal Laser
Description: Focal laser administered based on pre-specified criteria
Study NCT00118066 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: Given orally
Study NCT00118066 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: calcitriol
Description: Given orally
Study NCT00118066 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: observation
Description: No initial intervention
Study NCT02644161 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Antidepressant
Description: Patients will continue their existing antidepressant therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
Study NCT02644161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Patients will continue their existing rehabilitation therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.